At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 8 enrolled
Drug / intervention
Standard Dose YPT-01 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
CYstic Fibrosis bacterioPHage Study at Yale (CYPHY): A Single-site, Randomized, Double-blind, Placebo-controlled Study of Bacteriophage Therapy YPT-01 for Pseudomonas Aeruginosa Infections in Adults With Cystic Fibrosis
In Brief
A Phase 2 clinical trial evaluating Standard Dose YPT-01 and Placebo for Cystic Fibrosis. Completed, enrolled 8 participants across 1 site.
Detailed Summary
This is a Phase 2 study with primary objective of looking whether YPT-01 phage therapy reduces sputum bacterial load in cystic fibrosis subjects with Pseudomonas aeruginosa. In addition, study evaluates the safety profile of phage therapy in this patient population.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCystic Fibrosis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedDec 2020
Enrollment StartMar 2021
Primary CompletionMay 2023
Study CompletionJun 2023
TodayJul 2026
First PostedDec 24, 2020
Enrollment StartMar 29, 2021
Primary CompletionMay 26, 2023
Study CompletionJun 22, 2023
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 5.5 years ago
Interventions
Standard Dose YPT-01drug
Participants will be randomized to receive the standard dose of phage therapy YPT-01.
Placeboother
Participants will be randomized to receive the placebo.